PE20160855A1 - Quinazolin-thf-aminas como inhibidores de pde1 - Google Patents

Quinazolin-thf-aminas como inhibidores de pde1

Info

Publication number
PE20160855A1
PE20160855A1 PE2016000825A PE2016000825A PE20160855A1 PE 20160855 A1 PE20160855 A1 PE 20160855A1 PE 2016000825 A PE2016000825 A PE 2016000825A PE 2016000825 A PE2016000825 A PE 2016000825A PE 20160855 A1 PE20160855 A1 PE 20160855A1
Authority
PE
Peru
Prior art keywords
quinazolin
ethyl
methyl
amine
thf
Prior art date
Application number
PE2016000825A
Other languages
English (en)
Inventor
Jan Kehler
Lars Kyhn Rasmussen
Morten Langgard
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PE20160855A1 publication Critical patent/PE20160855A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referida a un compuesto derivado de quinazolin-amina de formula (I), donde R1 es H o alquilo C1-C3; R2 es H o alquilo C1-C3; R3 es H, metilo o etilo; R4 es H, OH, metoxi o etoxi; R5, R6 y R7 son H; R8 es H, metilo, etilo, ciclopropilo; R9 es es H, metilo o etilo. Son compuestos preferidos: 7,8-dimetoxi-N-(tetrahidrofuran-3il)quinazolin-4-amina, trans-N-(-2-ciclopropiltetrahidrofuran-3-il)-7,8-dimetoxiquinazolin-4-amina, entre otros. Dichos compuestos actuan como inhibidores de enzimas PDE1, siendo utiles para el tratamiento del trastorno por deficit de atencion con hiperactividad (TDAH), esquizofrenia o deterioro cognitivo asociado con la esquizofrenia, entre otros
PE2016000825A 2013-12-19 2014-12-18 Quinazolin-thf-aminas como inhibidores de pde1 PE20160855A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300707 2013-12-19
DKPA201400249 2014-05-06

Publications (1)

Publication Number Publication Date
PE20160855A1 true PE20160855A1 (es) 2016-09-23

Family

ID=52350066

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000825A PE20160855A1 (es) 2013-12-19 2014-12-18 Quinazolin-thf-aminas como inhibidores de pde1

Country Status (26)

Country Link
US (3) US9701665B2 (es)
EP (1) EP3083607B1 (es)
JP (1) JP6419832B2 (es)
KR (1) KR20160098269A (es)
CN (1) CN105829300B (es)
AP (1) AP2016009293A0 (es)
AU (1) AU2014368601B2 (es)
BR (1) BR112016013946A8 (es)
CA (1) CA2933299A1 (es)
CL (1) CL2016001488A1 (es)
CR (1) CR20160282A (es)
DO (1) DOP2016000152A (es)
EA (1) EA201691108A1 (es)
EC (1) ECSP16061208A (es)
ES (1) ES2728079T3 (es)
GE (1) GEP201706764B (es)
IL (1) IL246230A0 (es)
MX (1) MX2016007945A (es)
PE (1) PE20160855A1 (es)
PH (1) PH12016501173A1 (es)
RU (1) RU2016125315A (es)
SG (1) SG11201604936TA (es)
SV (1) SV2016005220A (es)
TN (1) TN2016000239A1 (es)
TW (1) TW201609713A (es)
WO (1) WO2015091805A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609713A (zh) 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺
ES2776359T3 (es) * 2014-04-04 2020-07-30 H Lundbeck As Quinazolin-thf-aminas halogenadas como inhibidores de PDE1
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
KR20200108419A (ko) 2017-11-27 2020-09-18 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211040A1 (en) * 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
CN1802177A (zh) * 2003-04-01 2006-07-12 应用研究系统Ars股份公司 用于不育症中的磷酸二酯酶抑制剂
US7517888B2 (en) * 2004-04-28 2009-04-14 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
CA2619462A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
US20090023756A1 (en) * 2006-02-23 2009-01-22 Pfizer Inc Substituted quinazolines as pde10 inhibitors
EP2279009A4 (en) * 2008-05-05 2011-09-21 Univ Rochester METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
JP2012526810A (ja) * 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2013505909A (ja) * 2009-09-24 2013-02-21 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物害虫を駆除するためのアミノキナゾリン化合物
TW201609713A (zh) 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺

Also Published As

Publication number Publication date
GEP201706764B (en) 2017-10-25
US9701665B2 (en) 2017-07-11
TN2016000239A1 (en) 2017-10-06
KR20160098269A (ko) 2016-08-18
US20150175584A1 (en) 2015-06-25
EA201691108A1 (ru) 2016-09-30
CR20160282A (es) 2016-09-06
MX2016007945A (es) 2016-10-12
BR112016013946A8 (pt) 2018-01-30
PH12016501173A1 (en) 2016-08-15
EP3083607A1 (en) 2016-10-26
US20170267664A1 (en) 2017-09-21
AU2014368601A1 (en) 2016-06-30
CA2933299A1 (en) 2015-06-25
AU2014368601B2 (en) 2018-07-05
WO2015091805A1 (en) 2015-06-25
JP6419832B2 (ja) 2018-11-07
SG11201604936TA (en) 2016-07-28
ES2728079T3 (es) 2019-10-22
ECSP16061208A (es) 2017-08-31
CN105829300B (zh) 2019-03-15
JP2017500339A (ja) 2017-01-05
IL246230A0 (en) 2016-08-02
CN105829300A (zh) 2016-08-03
SV2016005220A (es) 2016-11-30
BR112016013946A2 (pt) 2017-08-08
RU2016125315A (ru) 2018-01-24
US10030007B2 (en) 2018-07-24
US20160318910A1 (en) 2016-11-03
TW201609713A (zh) 2016-03-16
DOP2016000152A (es) 2016-09-30
CL2016001488A1 (es) 2016-12-09
EP3083607B1 (en) 2019-04-24
AP2016009293A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
CR20150192A (es) Moduladores de quinolinilo unidos a fenilo de ror-gamma-t
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
DOP2015000289A (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
CR20150279A (es) Lactamas fusionadas de arilo y heteroarilo
CR20150193A (es) Moduladores de quinolinilo unidos a metileno de ror-gamma-t
PE20150966A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
PE20160855A1 (es) Quinazolin-thf-aminas como inhibidores de pde1
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
UY33199A (es) 5-alquinil-pirimidinas.
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
ES2559857T3 (es) Nuevos inhibidores de galactósido de galectinas
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
PE20151748A1 (es) Inhibidores de bace1
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين

Legal Events

Date Code Title Description
FD Application declared void or lapsed